6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Aphasia
University of North Carolina, Chapel HillSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Aphasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LEVODOPA University Hospital Muenster | Phase 4 | BB |
Namenda Gabinete Berthier y Martínez | Phase 4 | BB |
Rotigotine I.R.C.C.S. Fondazione Santa Lucia | Phase 2 | B |
Cipralex Johns Hopkins University | Phase 2 | CCC |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
PITTSBURGH COMPOUND B UNLABELLED Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →